News - Proxygen

Fierce Biotech Names Proxygen a “Fierce 15” Biotech Company of 2023

28 August 2023 | Proxygen, a leader in the discovery and development of molecular glue degraders, today announced that Fierce Biotech has named it as one of 2023’s “Fierce 15” biotechnology companies. The annual special report features the most innovative and promising early-stage biotechnology companies in the industry […]

Proxygen announces collaboration and license agreement with MSD

05 April 2023 | Proxygen, a leader in the discovery and development of molecular glue degraders, announced today a multi-year research collaboration and license agreement with Merck & Co Inc., Rahway, N.J., USA, known as MSD outside the U.S. and Canada, to jointly identify and develop molecular glue degraders […]

Proxygen announces strategic collaboration with Merck

02 June 2022 | Proxygen, a leader in the discovery and development of molecular glue degraders, announced today that the company has entered into a strategic multi-year research collaboration and license agreement with Merck. […]

Boehringer Ingelheim collaborates with Proxygen

07 December 2020 | Boehringer Ingelheim and Proxygen today announced they have entered into a collaboration and license agreement to enable the identification of molecular glue degraders against various oncogenic targets. The collaboration combines […]

Boehringer Ingelheim awards Proxygen with BI Innovation Prize

31 July 2020 | The young biotech company Proxygen yesterday received the BI Innovation Prize for 12 months of free office and lab space in the new Start-Up Labs incubator at the Vienna BioCenter, […]